FluoGuide A/S (STO:FLUO)
Sweden · Delayed Price · Currency is SEK 40.50
-0.90 (-2.17%)
Oct 31, 2025, 12:35 PM CET
FluoGuide Company Description
FluoGuide A/S, a clinical stage biotechnology company, focuses on developing drugs for surgical outcomes by making cancer fluorescent in Denmark.
Its lead product candidate is FG001, which is in Phase IIa and IIb for the treatment of high-grade glioma; Phase II clinical trial for the treatment of lung cancer, and head and neck cancer.
FluoGuide A/S was incorporated in 2018 and is headquartered in Copenhagen, Denmark.
FluoGuide A/S
| Country | Denmark |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Morten Albrechtsen |
Contact Details
Address: Ole Maaløes Vej 3 Copenhagen, 2200 Denmark | |
| Phone | 45 31 22 66 60 |
| Website | fluoguide.com |
Stock Details
| Ticker Symbol | FLUO |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | DKK |
| ISIN Number | DK0061123312 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Morten Albrechtsen B.B.A., BBA, M.D. | Chief Executive Officer |
| Ole Larsen Cand. merc., M.Sc. | Chief Financial Officer |
| Prof. Andreas Kjaer M.D., M.Sc., Ph.D. | CSO, Head of Scientific Advisory Board and Director |
| Dr. Grethe Nørskov Rasmussen M.Sc., Ph.D. | Chief Development Officer |
| Dr. Jens Ellrich M.D., Ph.D. | Chief Medical Officer |
| Dorthe Gronnegaard Mejer | Vice President of Clinical Development |